Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE(®), Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). The Liverpool R...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacoecon Open
Main Authors: Fleeman, Nigel, Mahon, James, Nevitt, Sarah, Duarte, Rui, Boland, Angela, Kotas, Eleanor, Dundar, Yenal, McEntee, Joanne, Ahmad, Sajjad
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2019
Assuntos:
Review Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861391/
https://ncbi.nlm.nih.gov/pubmed/31240690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-0138-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares